SAN DIEGO, Nov. 22, 2024 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”) today announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) (“Evotec”) for €11.00 per share in cash, implying a fully diluted equity value of…